LMNL Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 sep 2023 @ 21:59):

Stats
Dagens volum	5 055.00
Gjennomsnittsvolum	23 725.00
Markedsverdi	27.62M
EPS	$0 ( 2024-03-13 )
Neste inntjeningsdato	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.245
ATR14	$0.0410 (0.48%)

Volum Korrelasjon

Lang: 0.13 (neutral)

Kort: -0.52 (weak negative)

Signal:(77.099) Neutral

Liminal BioSciences Inc Korrelasjon

10 Mest positive korrelasjoner
BCLI	0.848
GOODM	0.836
AEYE	0.833
BUFF	0.831
ACHV	0.828
RDWR	0.824
TBLD	0.819
CMPR	0.819
BOSC	0.815
TAYD	0.814

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Liminal BioSciences Inc Korrelasjon - Valuta/Råvare

-0.16
( neutral )

0.49
( neutral )

0.00
( neutral )

-0.04
( neutral )

0.21
( neutral )

0.20
( neutral )

Liminal BioSciences Inc Økonomi

Annual	2022
Omsetning:	$401 000
Bruttogevinst:	$401 000 (100.00 %)
EPS:	$-9.32

FY	2022
Omsetning:	$401 000
Bruttogevinst:	$401 000 (100.00 %)
EPS:	$-9.32

FY	2021
Omsetning:	$643 000
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$0.430

FY	2020
Omsetning:	$3.32M
Bruttogevinst:	$1.28M (38.71 %)
EPS:	$-4.83

Financial Reports:

No articles found.

Liminal BioSciences Inc

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.